HD
AstraZeneca fell more than 5% on Monday after the company revealed that it would acquire rare-disease specialist Alexion in a $39 billion deal.
AstraZeneca fell more than 5% on Monday after the company revealed that it would acquire rare-disease specialist Alexion in a $39 billion deal.
Contact your sales representative for commercial and promotional uses.